Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
breast cancer (46) 46
humans (46) 46
female (44) 44
index medicus (41) 41
oncology (35) 35
middle aged (32) 32
adult (27) 27
aged (24) 24
breast neoplasms - pathology (24) 24
breast neoplasms - drug therapy (23) 23
cancer (19) 19
breast neoplasms - genetics (16) 16
metastasis (16) 16
treatment outcome (16) 16
chemotherapy (14) 14
disease-free survival (13) 13
medicine & public health (13) 13
risk factors (13) 13
care and treatment (12) 12
case-control studies (12) 12
research (12) 12
clinical trials (11) 11
analysis (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
receptor, erbb-2 - metabolism (10) 10
women (10) 10
antimitotic agents (9) 9
antineoplastic agents (9) 9
breast neoplasms - metabolism (9) 9
breast neoplasms - mortality (9) 9
epidermal growth factor (9) 9
genome-wide association (9) 9
neoplasm staging (9) 9
survival (9) 9
tumors (9) 9
cancer therapies (8) 8
drug therapy (8) 8
genetic aspects (8) 8
health aspects (8) 8
postmenopausal women (8) 8
surgery (8) 8
surgical oncology (8) 8
therapy (8) 8
trastuzumab (8) 8
article (7) 7
breast neoplasms - surgery (7) 7
estrogen (7) 7
estrogen-receptor (7) 7
genetic predisposition to disease (7) 7
patients (7) 7
polymorphism, single nucleotide (7) 7
receptors, estrogen - metabolism (7) 7
alleles (6) 6
antineoplastic agents - therapeutic use (6) 6
cancer patients (6) 6
cancer research (6) 6
chemotherapy, adjuvant (6) 6
combination (6) 6
docetaxel (6) 6
drug administration schedule (6) 6
genetics (6) 6
genetics & heredity (6) 6
genome-wide association study (6) 6
oncology, experimental (6) 6
product development (6) 6
prognosis (6) 6
risk (6) 6
tamoxifen (6) 6
womens health (6) 6
adjuvant treatment (5) 5
aged, 80 and over (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
aromatase inhibitors (5) 5
asian continental ancestry group - genetics (5) 5
breast neoplasms - epidemiology (5) 5
cell line, tumor (5) 5
cyclophosphamide (5) 5
expression (5) 5
hematology, oncology and palliative medicine (5) 5
japan - epidemiology (5) 5
medical colleges (5) 5
metastases (5) 5
neoplasm metastasis (5) 5
radiation therapy (5) 5
retrospective studies (5) 5
survival analysis (5) 5
susceptibility loci (5) 5
taxoids - administration & dosage (5) 5
trial (5) 5
adolescent (4) 4
breast neoplasms - chemistry (4) 4
clinical medicine (4) 4
common variants (4) 4
confer susceptibility (4) 4
development and progression (4) 4
endocrine therapy (4) 4
epidemiology (4) 4
erbb-2 protein (4) 4
exemestane (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
by Cristofanilli, Massimo, Prof and Turner, Nicholas C, MD and Bondarenko, Igor, Prof and Ro, Jungsil, MD and Im, Seock-Ah, MD and Masuda, Norikazu, MD and Colleoni, Marco, MD and DeMichele, Angela, MD and Loi, Sherene, MD and Verma, Sunil, MD and Iwata, Hiroji, MD and Harbeck, Nadia, Prof and Zhang, Ke, PhD and Theall, Kathy Puyana, MD and Jiang, Yuqiu, PhD and Bartlett, Cynthia Huang, MD and Koehler, Maria, MD and Slamon, Dennis, Prof
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 425 - 439
Summary Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was associated with significant... 
Hematology, Oncology and Palliative Medicine | KINASE 4/6 INHIBITOR | SOUTHWEST-ONCOLOGY-GROUP | ONCOLOGY | RESISTANCE | PROGESTERONE-RECEPTOR | MUTATIONS | COMBINATION | AROMATASE INHIBITORS | EXPRESSION | ESTROGEN-RECEPTOR | CHEMOTHERAPY | Piperazines - administration & dosage | Estradiol - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Estradiol - administration & dosage | Treatment Outcome | Breast Neoplasms - drug therapy | Neoplasm Recurrence, Local - pathology | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Neoplasm Metastasis | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Breast Neoplasms - pathology | Adult | Female | Neoplasm Recurrence, Local - genetics | Aged | Mutation | Medical colleges | Care and treatment | Oncology, Experimental | Clinical trials | Breast cancer | Metastasis | Hormones | Research | Antineoplastic agents | Epidemiology | Antimitotic agents | Analysis | Product development | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
by Chan, Arlene, Prof and Delaloge, Suzette, MD and Holmes, Frankie A, MD and Moy, Beverly, MD and Iwata, Hiroji, MD and Harvey, Vernon J, MD and Robert, Nicholas J, MD and Silovski, Tajana, MD and Gokmen, Erhan, MD and von Minckwitz, Gunter, Prof and Ejlertsen, Bent, MD and Chia, Stephen K L, MD and Mansi, Janine, MD and Barrios, Carlos H, Prof and Gnant, Michael, Prof and Buyse, Marc, ScD and Gore, Ira, MD and Smith, John, MD and Harker, Graydon, MD and Masuda, Norikazu, MD and Petrakova, Katarina, MD and Zotano, Angel Guerrero, MD and Iannotti, Nicholas, MD and Rodriguez, Gladys, MD and Tassone, Pierfrancesco, Prof and Wong, Alvin, PharmD and Bryce, Richard, MBChB and Ye, Yining, PhD and Yao, Bin, MS and Martin, Miguel, Prof and ExteNET Study Grp and ExteNET Study Group
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 367 - 377
Summary Background Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive... 
Hematology, Oncology and Palliative Medicine | LAPATINIB | WOMEN | HERA TRIAL | ONCOLOGY | TYROSINE KINASE INHIBITOR | OPEN-LABEL | MINIMALLY IMPORTANT DIFFERENCES | COMBINATION | ESTROGEN-RECEPTOR | CHEMOTHERAPY | ONCOGENE ADDICTION | Breast Neoplasms - surgery | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Mastectomy - methods | Receptor, ErbB-2 - metabolism | Quinolines - administration & dosage | Dose-Response Relationship, Drug | Neoplasm Invasiveness - pathology | Adult | Female | Chemotherapy, Adjuvant | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - pathology | Internationality | Survival Analysis | Breast Neoplasms - mortality | Aged | Neoplasm Staging | Quinolines - adverse effects | Antimitotic agents | Tyrosine | Medical colleges | Care and treatment | Adjuvant treatment | Clinical trials | Product development | Breast cancer | Metastasis | College teachers | Antineoplastic agents | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
by Baselga, José, Prof and Im, Seock-Ah, Prof and Iwata, Hiroji, MD and Cortés, Javier, MD and De Laurentiis, Michele, MD and Jiang, Zefei, Prof and Arteaga, Carlos L, Prof and Jonat, Walter, Prof and Clemons, Mark, Prof and Ito, Yoshinori, MD and Awada, Ahmad, Prof and Chia, Stephen, MD and Jagiełło-Gruszfeld, Agnieszka, MD and Pistilli, Barbara, MD and Tseng, Ling-Ming, MD and Hurvitz, Sara, MD and Masuda, Norikazu, MD and Takahashi, Masato, MD and Vuylsteke, Peter, MD and Hachemi, Soulef, PhD and Dharan, Bharani, MS and Di Tomaso, Emmanuelle, PhD and Urban, Patrick, MD and Massacesi, Cristian, MD and Campone, Mario, Prof
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 904 - 916
Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast... 
Hematology, Oncology and Palliative Medicine | HETEROGENEITY | WOMEN | PALBOCICLIB | THERAPY | EXEMESTANE | ONCOLOGY | MUTATION | RESISTANCE | COMBINATION | AROMATASE INHIBITORS | PI3K INHIBITOR | Estradiol - analogs & derivatives | Humans | Middle Aged | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Receptors, Estrogen - analysis | Fulvestrant | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Neoplasm Metastasis | Hyperglycemia - chemically induced | DNA, Neoplasm - blood | DNA Mutational Analysis | Exanthema - chemically induced | Postmenopause | Female | Morpholines - adverse effects | Aminopyridines - administration & dosage | Drug Eruptions - etiology | Double-Blind Method | Morpholines - administration & dosage | Estradiol - administration & dosage | Survival Rate | Signal Transduction - genetics | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Retreatment | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Aspartate Aminotransferases - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Clinical trials | Product development | Breast cancer | Postmenopausal women | Hormones | Antineoplastic agents | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial
by Masuda, Norikazu, MD and Sagara, Yasuaki, MD and Kinoshita, Takayuki, MD and Iwata, Hiroji, MD and Nakamura, Seigo, Prof and Yanagita, Yasuhiro, MD and Nishimura, Reiki, MD and Iwase, Hirotaka, Prof and Kamigaki, Shunji, MD and Takei, Hiroyuki, MD and Noguchi, Shinzaburo, Prof
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 4, pp. 345 - 352
Summary Background Aromatase inhibitors have shown increased efficacy compared with tamoxifen in postmenopausal early breast cancer. We aimed to assess the... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | CYCLOPHOSPHAMIDE | ADJUVANT ENDOCRINE THERAPY | METHOTREXATE | FOLLOW-UP | QUALITY-OF-LIFE | POSTMENOPAUSAL WOMEN | COMBINATION | FLUOROURACIL | PLUS ZOLEDRONIC ACID | AROMATASE INHIBITORS | Aromatase Inhibitors - administration & dosage | Neoplasms, Hormone-Dependent - surgery | Breast Neoplasms - surgery | Goserelin - administration & dosage | Triazoles - administration & dosage | Triazoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Premenopause | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Breast Neoplasms - drug therapy | Tamoxifen - administration & dosage | Nitriles - administration & dosage | Breast Neoplasms - pathology | Adult | Female | Neoadjuvant Therapy | Neoplasms, Hormone-Dependent - drug therapy | Neoplasm Staging | Nitriles - adverse effects | Antimitotic agents | Menopause | Clinical trials | Product development | Breast cancer | Postmenopausal women | Tamoxifen | Antineoplastic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer
by Michailidou, Kyriaki and Beesley, Jonathan and Lindstrom, Stephen and Canisius, Sander and Dennis, Joe and Lush, Michael and Maranian, Melanie and Bolla, Manjeet and Wang, Qing and Shah, Mitul and Perkins, Barbara and Czene, Kamila and Eriksson, Mikael and Darabi, Hatef and Brand, Judith S and Bojesen, Stig and Nordestgaard, Børge and Flyger, Henrik and Nielsen, Sune and Rahman, Nazneen and Turnbull, Clare and Fletcher, Olivia and Peto, Julian and Gibson, Lorna and Santos Silva, Isabel and Chang-Claude, Jenny and Flesch-Janys, Dieter and Rudolph, Anja and Eilber, Ursula and Behrens, Timothy and Nevanlinna, Heli and Muranen, Taru and Aittomäki, Kristiina and Blomqvist, Carl and Khan, Sofia and Aaltonen, Kirsimari and Ahsan, Habibul and Kibriya, Muhammad and Whittemore, Alice S and John, Esther M and Malone, Kathleen E and Gammon, Marilie and Santella, Regina M and Ursin, Giske and Makalic, Enes and Schmidt, Daniel and Casey, Graham and Hunter, David J and Gapstur, Susan M and Gaudet, Mia and Diver, Ryan and Haiman, Christopher A and Schumacher, Freick and Henderson, Brian and Le Marchand, Loic and Berg, Christine and Chanock, Stephen and Figueroa, Jonine and Hoover, Robert N and Lambrechts, Diether and Neven, Patrick and Wildiers, Hans and Limbergen, Erik and Schmidt, Marjanka and Broeks, Annegien and Verhoef, S and Cornelissen, Sten and Couch, Fergus and Olson, Janet and Hallberg, Boubou and Vachon, Celine and Waisfisz, Quinten and Meijers-Heijboer, Hanne and Adank, Muriel and Luijt, Rob and Li, Jingmei and Liu, Jianjun and Humphreys, Manjeet and Kang, Daehee and Choi, Ji-Yeob and Park, Sue K and Yoo, K.Y and Matsuo, Keitaro and Ito, Hidemi and Iwata, Hiroji and Tajima, Kazuo and Guénel, Pascal and Truong, Thérèse and Mulot, Claire and Sanchez, Marie and Burwinkel, Barbara and Marme, Federick and Surowy, Harald and Sohn, Christof and Wu, Anna H and Tseng, Chiu-chen and Van Den Berg, David and Stram, Daniel O and González-Neira, Anna and Benítez, Javier and ... and KConFab Investigators and AOCS Grp and BOCS and NBCS and GENICA Network and kConFab Investigators and AOCS Group and Medicinska fakulteten and Kirurgi and Institutionen för kirurgisk och perioperativ vetenskap and Umeå universitet
Nature Genetics, ISSN 1061-4036, 04/2015, Volume 47, Issue 4, pp. 373 - 380
textabstractGenome-wide association studies (GWAS) and large-scale replication studies have identified common variants in 79 loci associated with breast... 
COMMON VARIANTS | ALLELES | METAANALYSIS | GENOTYPE IMPUTATION | GENETICS & HEREDITY | ESTROGEN | CONFER SUSCEPTIBILITY | RISK | OVARIAN-CANCER | BRCA1 | CHEK2-ASTERISK-1100DELC | Genetic Predisposition to Disease | Genome-Wide Association Study | Meta-Analysis as Topic | Breast Neoplasms - genetics | Microarray Analysis | Humans | Female | Polymorphism, Single Nucleotide | Genetic Loci | Case-Control Studies | Cohort Studies | Quantitative trait loci | Genetic susceptibility | Genetic research | Breast cancer | Genetic aspects | Research | Identification and classification | Risk factors | Studies | Datasets | Genealogy | Disease | Womens health | Genes | Genomes | Index Medicus | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
by Bojesen, Stig E and Pooley, Karen A and Johnatty, Sharon E and Beesley, Jonathan and Michailidou, Kyriaki and Tyrer, Jonathan P and Edwards, Stacey L and Pickett, Hilda A and Shen, Howard C and Smart, Chanel E and Hillman, Kristine M and Mai, Phuong L and Lawrenson, Kate and Stutz, Michael D and Lu, Yi and Karevan, Rod and Woods, Nicholas and Johnston, Rebecca L and French, Juliet D and Chen, Xiaoqing and Weischer, Maren and Nielsen, Sune F and Maranian, Melanie J and Ghoussaini, Maya and Ahmed, Shahana and Baynes, Caroline and Bolla, Manjeet K and Wang, Qin and Dennis, Joe and McGuffog, Lesley and Barrowdale, Daniel and Lee, Anew and Healey, Sue and Lush, Michael and Tessier, Daniel C and Vincent, Daniel and Bacot, Françis and Vergote, Ignace and Lambrechts, Sanina and Despierre, Evelyn and Risch, Harvey A and González-Neira, Anna and Rossing, Mary Anne and Pita, Guillermo and Doherty, Jennifer A and Alvarez, Nuria and Larson, Melissa C and Fridley, Brooke L and Schoof, Nils and Chang-Claude, Jenny and Cicek, Mine S and Peto, Julian and Kalli, Kimberly R and Broeks, Annegien and Armasu, Sebastian M and Schmidt, Marjanka K and Braaf, Linde M and Winterhoff, Boris and Nevanlinna, Heli and Konecny, Gottfried E and Lambrechts, Diether and Rogmann, Lisa and Guénel, Pascal and Teoman, Attila and Milne, Roger L and Garcia, Joaquin J and Cox, Angela and Shridhar, Vijayalakshmi and Burwinkel, Barbara and Marme, Frederik and Hein, Rebecca and Sawyer, Elinor J and Haiman, Christopher A and Wang-Gohrke, Shan and Anulis, Irene L and Moysich, Kirsten B and Hopper, John L and Odunsi, Kunle and Lindblom, Annika and Giles, Graham G and Brenner, Hermann and Simard, Jacques and Lurie, Galina and Fasching, Peter A and Carney, Michael E and Radice, Paolo and Wilkens, Lynne R and Swerdlow, Anthony and Goodman, Marc T and Brauch, Hiltrud and Garcia-Closas, Montserrat and Hillemanns, Peter and Winqvist, Robert and Dürst, Matthias and Devilee, Peter and Runnebaum, Ingo and Jakubowska, Anna and Lubinski, Jan and Mannermaa, Arto and Butzow, Ralf and ... and Gene Environm Interactimi Breast and Kathleen Cuningham Fdn Consortium and Australian Ovarian Canc Study and Epidemiological Study BRCA1 and Hereditary Breast Ovarian Canc Res and Genetic Modifiers Canc Risk BRCA1 and Australian Canc Study and Swedish Breast Canc Study SWE-BRCA and The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) and Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO) and Gene Environment Interaction and Breast Cancer (GENICA) and Swedish Breast Cancer Study (SWE-BRCA) and Epidemiological study of BRCA1 & BRCA2 Mutation Carriers (EMBRACE) and Australian Ovarian Cancer Study and Australian Cancer Study and Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) and Medicinska fakulteten and Umeå universitet and Institutionen för strålningsvetenskaper
Nature genetics, ISSN 1061-4036, 2013, Volume 45, Issue 4, pp. 371 - 384
TERT-locus SNPs and leukocyte telomere measures are reportedly associated with risks of multiple cancers. Using the Illumina custom genotyping array iCOGs, we... 
BUCCAL CELLS | GENETIC-VARIATION | COMMON VARIANTS | TERT-CLPTM1L LOCUS | REVERSE-TRANSCRIPTASE | SEQUENCE | GENETICS & HEREDITY | SUSCEPTIBILITY LOCI | POLYMORPHISM | FIBROBLASTS | GENOME-WIDE ASSOCIATION | Breast cancer | Genetic aspects | Research | Single nucleotide polymorphisms | Risk factors | Ovarian cancer | Genetics | Mutation | Càncer de mama | Càncer d'ovari | Telòmer | Telomere | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text ASO Author Reflections: The Strengths and Weaknesses of Intraoperative Radiotherapy for Early Breast Cancer and Ipsilateral Tumor Recurrence
by Sawaki, Masataka and Kodaira, Takeshi and Iwata, Hiroji
Annals of surgical oncology, ISSN 1068-9265, 07/2019
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Replication and functional genomic analyses of the breast cancer susceptibility locus at 6q25.1 generalize its importance in women of Chinese, Japanese, and European ancestry
by Cai, Qiuyin and Wen, Wanqing and Qu, Shimian and Li, Guoliang and Egan, Kathleen M and Chen, Kexin and Deming, Sandra L and Shen, Hongbing and Shen, Chen-Yang and Gammon, Marilie D and Blot, William J and Matsuo, Keitaro and Haiman, Christopher A and Khoo, Ui Soon and Iwasaki, Motoki and Santella, Regina M and Zhang, Lina and Fair, Alecia Malin and Hu, Zhibin and Wu, Pei-Ei and Signorello, Lisa B and Titus-Ernstoff, Linda and Tajima, Kazuo and Henderson, Brian E and Chan, Kelvin Y. K and Kasuga, Yoshio and Newcomb, Polly A and Zheng, Hong and Cui, Yong and Wang, Furu and Shieh, Ya-Lan and Iwata, Hiroji and Le Marchand, Loic and Chan, Sum Yin and Shrubsole, Martha J and Trentham-Dietz, Amy and Tsugane, Shoichiro and Garcia-Closas, Montserrat and Long, Jirong and Li, Chun and Shi, Jiajun and Huang, Bo and Xiang, Yong-Bing and Gao, Yu-Tang and Lu, Wei and Shu, Xiao-Ou and Zheng, Wei
Cancer Research, ISSN 0008-5472, 02/2011, Volume 71, Issue 4, pp. 1344 - 1355
We evaluated the generalizability of a single nucleotide polymorphism (SNP), rs2046210 (A/G allele), associated with breast cancer risk that was initially... 
POLYMORPHISMS | ONCOLOGY | RISK | GENETIC-VARIANTS | COHORT | WIDE ASSOCIATION | ER-ALPHA | European Continental Ancestry Group - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Humans | Middle Aged | Asian Continental Ancestry Group - genetics | Genotype | Case-Control Studies | Chromosomes, Human, Pair 6 - genetics | Breast Neoplasms - genetics | Carcinoma - ethnology | Carcinoma - epidemiology | Carcinoma - genetics | Female | Polymorphism, Single Nucleotide | Genomics - methods | Breast Neoplasms - ethnology | Breast Neoplasms - epidemiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Current approach and future perspective for ductal carcinoma in situ of the breast
by Kanbayashi, Chizuko and Iwata, Hiroji
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 08/2017, Volume 47, Issue 8, pp. 671 - 677
Ductal carcinoma in situ (DCIS) has a good prognosis with the current treatment approach, with a 10-year breast cancer-specific survival rate of 97-98%. In... 
Clinical trial | Ductal carcinoma in situ | Breast cancer | Low grade DCIS | Overtreatment | clinical trial | SURGICAL ADJUVANT BREAST | LONG-TERM OUTCOMES | PHASE-III | breast cancer | FOLLOW-UP | CANCER | ductal carcinoma in situ | low grade DCIS | CORE-NEEDLE-BIOPSY | ONCOLOGY | DOUBLE-BLIND | LYMPH-NODE BIOPSY | RADIOTHERAPY | POSTMENOPAUSAL WOMEN | overtreatment | Breast Neoplasms - therapy | Breast Neoplasms - surgery | Carcinoma, Intraductal, Noninfiltrating - pathology | Carcinoma, Intraductal, Noninfiltrating - therapy | Early Detection of Cancer - methods | Breast Neoplasms - pathology | Humans | Female | Carcinoma, Intraductal, Noninfiltrating - surgery | Mammography - methods | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers
by French, Juliet D and Ghoussaini, Maya and Edwards, Stacey L and Meyer, Kerstin B and Michailidou, Kyriaki and Ahmed, Shahana and Khan, Sofia and Maranian, Mel J and O’Reilly, Martin and Hillman, Kristine M and Betts, Joshua A and Carroll, Thomas and Bailey, Peter J and Dicks, Ed and Beesley, Jonathan and Tyrer, Jonathan and Maia, Ana-Teresa and Beck, Andrew and Knoblauch, Nicholas W and Chen, Shou-Tung and Chen, Constance and Kraft, Peter and Barnes, Daniel and González-Neira, Anna and Alonso, M. Rosario and Herrero, Daniel and Tessier, Daniel C and Vincent, Daniel and Bacot, Francois and Luccarini, Craig and Baynes, Caroline and Conroy, Don and Dennis, Joe and Bolla, Manjeet K and Wang, Xianshu and Wang, Qin and Hopper, John L and Southey, Melissa C and Schmidt, Marjanka K and Broeks, Annegien and Verhoef, Senno and Cornelissen, Sten and Muir, Kenneth and Lophatananon, Artitaya and Stewart-Brown, Sarah and Siriwanarangsan, Pornthep and Fasching, Peter A and Loehberg, Christian R and Ekici, Arif B and Beckmann, Matthias W and Peto, Julian and dos Santos Silva, Isabel and Johnson, Nichola and Aitken, Zoe and Sawyer, Elinor J and Tomlinson, Ian and Kerin, Michael J and Miller, Nicola and Marme, Frederik and Schneeweiss, Andreas and Sohn, Christof and Burwinkel, Barbara and Guénel, Pascal and Truong, Thérèse and Laurent-Puig, Pierre and Menegaux, Florence and Bojesen, Stig E and Nordestgaard, Børge G and Nielsen, Sune F and Flyger, Henrik and Milne, Roger L and Zamora, M. Pilar and Arias Perez, Jose Ignacio and Benitez, Javier and Anton-Culver, Hoda and Brenner, Hermann and Müller, Heiko and Arndt, Volker and Stegmaier, Christa and Meindl, Alfons and Lichtner, Peter and Schmutzler, Rita K and Engel, Christoph and Brauch, Hiltrud and Hamann, Ute and Justenhoven, Christina and Aaltonen, Kirsimari and Heikkilä, Päivi and Aittomäki, Kristiina and Blomqvist, Carl and Matsuo, Keitaro and Ito, Hidemi and Iwata, Hiroji and Sueta, Aiko and Bogdanova, Natalia V and Antonenkova, Natalia N and Dörk, Thilo and Lindblom, Annika and Margolin, Sara and Mannermaa, Arto and ... and KConFab Investigators and GENICA Network and kConFab Investigators
The American Journal of Human Genetics, ISSN 0002-9297, 04/2013, Volume 92, Issue 4, pp. 489 - 503
Analysis of 4,405 variants in 89,050 European subjects from 41 case-control studies identified three independent association signals for... 
GENE | GENETICS & HEREDITY | DOWN-REGULATION | GROWTH-FACTOR RECEPTOR-2 | ALPHA | MULTIPLE LOCI | CELL-CYCLE | DIFFERENTIATION | ESTROGEN-RECEPTOR | GATA-3 | GENOME-WIDE ASSOCIATION | GATA3 Transcription Factor - genetics | Cyclin D1 - metabolism | RNA, Small Interfering - genetics | Luciferases - metabolism | ets-Domain Protein Elk-4 - genetics | Humans | Gene Expression Regulation, Neoplastic | ets-Domain Protein Elk-4 - metabolism | Promoter Regions, Genetic - genetics | Case-Control Studies | Chromatin Immunoprecipitation | GATA3 Transcription Factor - antagonists & inhibitors | Female | Electrophoretic Mobility Shift Assay | Binding Sites | GATA3 Transcription Factor - metabolism | Real-Time Polymerase Chain Reaction | Chromatin - chemistry | RNA, Messenger - genetics | Silencer Elements, Transcriptional - genetics | Chromosomes, Human, Pair 11 - genetics | Reverse Transcriptase Polymerase Chain Reaction | ets-Domain Protein Elk-4 - antagonists & inhibitors | Breast Neoplasms - genetics | Cyclin D1 - genetics | Cell Line, Tumor | Polymorphism, Single Nucleotide - genetics | Enhancer Elements, Genetic - genetics | Chromatin - genetics | Health aspects | Breast cancer | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights